Solasto Corp. (JP:6197)
:6197
Top Page
Solasto Corp.
(6197)
Select Model
Select Model
Rating:68Neutral
Price Target:
¥1,094.00
▲(118.36% Upside)
Action:DowngradedDate:02/18/26
The score is driven primarily by improving financial performance (rapid TTM revenue growth, better operating margin, strong cash conversion, and reduced leverage). Technicals are mixed with short-term weakness but a still-supportive longer-term uptrend, while valuation appears reasonable but not notably discounted.
Positive Factors
Revenue acceleration
A near‑term but durable surge in TTM revenue (+74.8%) indicates materially stronger demand or successful market expansion. Sustained top‑line momentum improves scale economics, supports reinvestment in operations and services, and underpins medium‑term growth plans.
Negative Factors
Thin profitability
Net margins near 3.2% and a declining gross margin lower the company’s earnings buffer. With slim margins, the business is highly sensitive to input cost inflation, reimbursement changes, or pricing pressure, which can quickly erode cash flow and constrain strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue acceleration
A near‑term but durable surge in TTM revenue (+74.8%) indicates materially stronger demand or successful market expansion. Sustained top‑line momentum improves scale economics, supports reinvestment in operations and services, and underpins medium‑term growth plans.
Read all positive factors
Solasto Corp. (6197) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥104.59B
Dividend Yield2.47%
Average Volume (3M)1.21M
Price to Earnings (P/E)16.0
Beta (1Y)0.65
Revenue Growth1.86%
EPS Growth1370.48%
CountryJP
Employees33,884
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)13.23
Shares Outstanding94,741,790
10 Day Avg. Volume3,043,910
30 Day Avg. Volume1,212,820
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.86
Price to Sales (P/S)0.31
P/FCF Ratio7.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)44.7
Revenue Forecast (FY)¥140.50B
Solasto Corp. Business Overview & Revenue Model
Company Description
Solasto Corp. (6197) is a leading provider of healthcare services in Japan, focusing primarily on the management of medical facilities and the provision of various healthcare-related solutions. The company operates in multiple sectors including ou...
How the Company Makes Money
null...
Solasto Corp. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 140.12B | 137.44B | 135.14B | 131.09B | 117.24B | 106.18B |
| Gross Profit | 20.96B | 20.75B | 20.11B | 20.02B | 19.06B | 17.57B |
| EBITDA | 10.02B | 10.13B | 8.86B | 9.46B | 8.92B | 8.40B |
| Net Income | 4.24B | 3.96B | 2.26B | 3.17B | 3.50B | 3.54B |
Balance Sheet | ||||||
| Total Assets | 68.75B | 70.10B | 75.20B | 69.85B | 70.75B | 60.10B |
| Cash, Cash Equivalents and Short-Term Investments | 12.40B | 14.00B | 15.12B | 11.96B | 10.34B | 8.97B |
| Total Debt | 16.73B | 23.29B | 28.52B | 25.89B | 28.65B | 21.75B |
| Total Liabilities | 45.10B | 47.41B | 54.71B | 48.28B | 50.59B | 41.63B |
| Stockholders Equity | 23.64B | 22.68B | 20.48B | 21.57B | 20.15B | 18.47B |
Cash Flow | ||||||
| Free Cash Flow | 7.10B | 5.46B | 6.64B | 7.98B | 5.25B | 6.20B |
| Operating Cash Flow | 7.43B | 5.88B | 7.86B | 9.01B | 5.52B | 6.73B |
| Investing Cash Flow | -908.00M | 347.00M | -2.76B | -2.17B | -7.45B | -3.82B |
| Financing Cash Flow | -7.41B | -7.33B | -1.84B | -5.21B | 3.20B | -5.72B |
Solasto Corp. Technical Analysis
Neutral
501.00
Price Trends
939.54
Positive
808.63
Positive
630.99
Positive
Market Momentum
9.24
Positive
48.04
Neutral
21.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6197, the sentiment is Neutral. The current price of 501 is below the 20-day moving average (MA) of 980.30, below the 50-day MA of 939.54, and below the 200-day MA of 630.99, indicating a neutral trend. The MACD of 9.24 indicates Positive momentum. The RSI at 48.04 is Neutral, neither overbought nor oversold. The STOCH value of 21.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:6197.
Solasto Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥44.38B | 14.67 | 20.80% | 1.77% | 16.49% | 3.34% | |
72 Outperform | ¥43.30B | 11.61 | ― | 2.63% | 0.30% | -31.28% | |
68 Neutral | ¥104.59B | 16.02 | ― | 2.47% | 1.86% | 1370.48% | |
62 Neutral | ¥42.27B | 10.69 | ― | 0.91% | 15.77% | -50.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥5.85B | 23.20 | ― | 4.07% | 6.08% | 38.00% |
* Healthcare Sector Average
JP:6197
Solasto Corp.
1,104.00
641.41
138.66%
JP:6099
Elan Corp.
734.00
-3.78
-0.51%
JP:2373
Care Twentyone Corporation
435.00
39.91
10.10%
JP:6062
Charm Care Corporation
1,328.00
15.59
1.19%
JP:7071
Amvis Holdings.Inc.
430.00
-28.96
-6.31%
Solasto Corp. Corporate Events
Solasto Updates Progress on Ongoing Share Buy-Back Program
Mar 2, 2026
Solasto Corporation has reported the latest progress of its ongoing share buy-back program authorized by its board in August 2025, which allows repurchases of up to 4.4 million shares, or 4.8% of outstanding stock, for a total of up to ¥1.4 b...
Solasto lifts FY2025 Q3 profit and keeps outlook, raises annual dividend
Feb 10, 2026
Solasto Corporation reported consolidated net sales of ¥105.6 billion for the first nine months of FY2025, up 2.6% year on year, while operating profit edged down 1.9% to ¥5.5 billion and ordinary profit rose 2.2% to ¥5.5 billion, l...
Solasto Continues Share Buy-Back, Repurchasing 1.49 Million Shares to Date
Feb 2, 2026
Solasto Corporation has disclosed the latest progress of its ongoing share buy-back program authorized by its board in August 2025, reporting that it repurchased 169,900 shares of common stock for a total of ¥148.4 million via market purchase...
Solasto Finalizes Terms of Children Business Spin-Off to Solasto KIDS NEXT
Jan 16, 2026
Solasto Corporation has approved and signed an absorption-type company split agreement to spin off its Children business into a wholly owned subsidiary, Solasto KIDS NEXT Corporation, with the split scheduled to take effect on April 1, 2026. The c...
Solasto Revamps Corporate Officer Structure and Creates New Business Operations Division
Jan 16, 2026
Solasto Corporation has announced a new corporate officer structure, effective April 1, 2026, following recommendations from its Nomination, Evaluation, and Compensation Committee and approval by the Board of Directors. President and CEO Toru Noda...
Solasto Reports Progress on Ongoing Share Buyback Program
Jan 5, 2026
Solasto Corporation has reported the latest progress on its ongoing share buyback program authorized by its board in August 2025. During the period from December 1 to December 31, 2025, the company repurchased 172,800 shares of its common stock on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.